Abstract
Neratinib is an orally administered, small-molecule, irreversible pan-ErbB inhibitor in development for the treatment of ErbB2-positive breast cancer. This study assessed the effects of therapeutic and supratherapeutic neratinib concentrations on cardiac repolarization, in accordance with current regulatory guidance. This was a two-part study in healthy subjects. In part 1, subjects were randomized to receive placebo, 400 mg moxifloxacin, or 240 mg neratinib (therapeutic dose) following a high-fat meal. In part 2, after a washout period, subjects received placebo plus 400 mg ketoconazole or 240 mg neratinib plus ketoconazole (supratherapeutic dose). ANOVA was used to compare the baseline-adjusted QTc interval for neratinib with that of placebo (reference), and for neratinib plus ketoconazole with that of placebo plus ketoconazole (reference). Pharmacokinetic/pharmacodynamic analyses and categorical summaries of interval data were done. Assay sensitivity was evaluated by the effect of moxifloxacin on QTc compared with placebo. Sixty healthy subjects were enrolled in this study. The upper bounds of the 90% confidence interval for baseline-adjusted QTcN (population-specific corrected QT) were </=10 milliseconds greater than the co...Continue Reading
References
Aug 4, 1998·Antimicrobial Agents and Chemotherapy·H StassU Schühly
May 9, 2000·Clinical Pharmacology and Therapeutics·R E BentonR L Woosley
Sep 5, 2002·British Journal of Clinical Pharmacology·Rashmi R Shah
Jun 3, 2004·Cancer Research·Sridhar K RabindranAllan Wissner
Feb 18, 2005·Journal of Medicinal Chemistry·Hwei-Ru TsouAllan Wissner
Jul 30, 2005·Cancer Letters·Sridhar K Rabindran
May 19, 2006·Journal of Clinical Pharmacology·Borje DarpoDiane K Jorkasky
Nov 21, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Giuseppe CuriglianoRashmi Shah
Jun 6, 2008·Mayo Clinic Proceedings·Edith A PerezMichael S Ewer
Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kwok-K WongHoward A Burris
Nov 6, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pamela N MunsterMarian Iwamoto
Nov 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carlo L BelloLee Rosen
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinRajendra Badwe
Citations
Mar 1, 2012·Cancer Chemotherapy and Pharmacology·Joseph P BoniDaryl Sonnichsen
Mar 16, 2012·Cancer Chemotherapy and Pharmacology·Richat AbbasDaryl Sonnichsen
Oct 12, 2012·Cancer Chemotherapy and Pharmacology·Richat AbbasDaryl Sonnichsen
Oct 3, 2013·Cancer Chemotherapy and Pharmacology·L Rhoda MolifeJames Spicer
Sep 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A AwadaE Staroslawska
Jul 27, 2011·PloS One·Hua XieJian Ding
Jul 7, 2012·Future Oncology·Sara López-TarruellaMiguel Martín
Aug 14, 2012·Clinical Therapeutics·Richat AbbasDaryl Sonnichsen
Nov 9, 2011·International Journal of Cancer. Journal International Du Cancer·Richat AbbasDaryl Sonnichsen
Apr 4, 2015·Acta Pharmacologica Sinica·Qian ChenJing-ying Jia
Mar 1, 2012·Journal of Electrocardiology·Pooja HingoraniSnehal Kothari
Aug 21, 2015·PloS One·Jörg TäubelA John Camm
Jun 11, 2016·Expert Opinion on Drug Metabolism & Toxicology·Hampig Raphael KourieAhmad Awada
Aug 2, 2016·Oral Diseases·S SchneiderG Heiduschka
Oct 4, 2016·Expert Opinion on Pharmacotherapy·Annemie Prové, Luc Dirix
Apr 13, 2018·Angewandte Chemie·Karim AljakouchKlaus Gerwert
Nov 2, 2019·Clinical and Translational Science·Mariam A AhmedDaria Stypinski
Oct 30, 2018·Clinical Drug Investigation·Zhihang TaoXuelei Ma
Sep 9, 2017·Drugs·Emma D Deeks
Oct 31, 2017·Cancer Chemotherapy and Pharmacology·Jan de JongDaniele Ouellet